Drug Design, Development and Therapy (Aug 2022)
Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies
Abstract
Evdoxia-Maria Karasavvidou,1 Paris Tranos,2 Georgios D Panos3 1Karasavvidou Eye Centre, Naousa, Greece; 2Ophthalmica Eye Institute, Thessaloniki, Greece; 3Department of Ophthalmology, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UKCorrespondence: Georgios D Panos, Department of Ophthalmology, Queen’s Medical Centre, Derby Road, Lenton, Nottingham, NG7 2UH, UK, Tel +44 115 924 9924, Email [email protected]: Age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusion represent some of the commonest degenerative conditions that lead to severe vision impairment in the developed countries. The gold standard treatment of complications associated with these conditions is the intravitreal administration of anti-vascular endothelial growth factor (VEGF) agents. Brolucizumab is a newly developed, humanised, single-chain fragment of a monoclonal antibody binding all VEGF-A isoforms, which was recently approved for the treatment of neovascular AMD. Intravitreal brolucizumab promises to reduce treatment burden for nAMD patients by achieving comparable therapeutic outcomes with fewer clinic visits. Promising also appears its use for the treatment of more challenging maculopathies like diabetic macular oedema (DMO). The aim of this review is to describe the special pharmacological properties of brolucizumab and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of degenerative macular disorders.Keywords: degenerative macular disorders, brolucizumab, anti-VEGF, efficacy, safety, intravitreal treatment
